What's Happening?
SV Health Investors, a private investment firm focused on healthcare and life sciences, has acquired EpiVax, Inc., a bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies. EpiVax, headquartered in Providence,
RI, has been a pioneer in pre-clinical drug development for over 25 years. The acquisition represents a new platform investment for SV Health Investors, building on their experience in outsourced pharma services. EpiVax's founder, Annie De Groot, expressed confidence in SV Health Investors' ability to advance the company, while SVHI's partner, A.J. Rossi, highlighted the firm's strategic guidance and capital support for EpiVax's growth.
Why It's Important?
The acquisition of EpiVax by SV Health Investors is significant as it strengthens SVHI's position in the healthcare sector, particularly in outsourced pharma services. EpiVax's expertise in immunogenicity risk assessment is crucial for pharmaceutical and biotech companies aiming to reduce timelines and R&D costs. This move aligns with SVHI's strategy to partner with management teams to build industry-leading healthcare businesses. The acquisition could lead to enhanced capabilities and services at EpiVax, benefiting global pharma and biotech partners in developing regulatory-ready strategies.
What's Next?
EpiVax plans to expand its capabilities and services, including launching advanced computational tools and broader analytical consulting services. The collaboration with SVHI is expected to accelerate EpiVax's growth and innovation, enhancing its ability to support global partners. Legal advisors Morgan Lewis & Bockius LLP and Foley & Lauder LLP facilitated the acquisition process.
